Guangdong taienkang Pharmaceutical Co., Ltd
Online roadshow announcement of initial public offering and listing on GEM
Sponsor (lead underwriter): Guotai Junan Securities Co.Ltd(601211)
The application of Guangdong taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as “the issuer”, “taienkang” and “the company”) for the initial public offering of 59.1 million RMB common shares (A shares) (hereinafter referred to as “this offering”) has been examined and approved by the Municipal Committee on the gem of Shenzhen Stock Exchange, It has been approved to register by China Securities Regulatory Commission (hereinafter referred to as “CSRC”) (zjxk [2022] No. 203).
This offering is conducted by a combination of directional placement to strategic investors (hereinafter referred to as “strategic placement”), offline inquiry placement to qualified investors (hereinafter referred to as “offline issuance”) and online pricing issuance to social public investors holding non restricted A-share shares or non restricted depositary receipts market value in Shenzhen market (hereinafter referred to as “online issuance”).
The strategic placement of this issuance refers to the special asset management plan established by the issuer’s senior managers and core employees participating in this strategic placement. If the offering price exceeds the median and weighted average of offline investors’ quotation after excluding the highest quotation, as well as the securities investment fund, national social security fund, basic old-age insurance fund established through public offering after excluding the highest quotation For the enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund and the insurance fund quotation median and weighted average in accordance with the measures for the administration of the use of insurance funds, whichever is lower, the relevant subsidiaries of the sponsor will participate in the strategic placement of this issuance in accordance with the relevant provisions. The issuer and the sponsor (lead underwriter) will disclose the total amount of shares, the number of subscriptions, the proportion in the number of shares issued this time and the holding period in the announcement on the initial public offering of Guangdong taienkang Pharmaceutical Co., Ltd. and its listing on the gem (hereinafter referred to as the “issuance announcement”).
59.1 million shares were issued in this public offering, accounting for 25% of the total share capital after issuance, and the total share capital after this public offering was 2363875 million shares. The initial number of strategic placement shares issued in this issuance is 8.865 million shares, accounting for 15% of this issuance. It is only composed of the special asset management plan established by the issuer’s senior managers and core employees participating in this strategic placement and the follow-up investment of relevant subsidiaries of the sponsor (if any). The difference between the final placement quantity and the initial placement quantity of strategic investors is transferred back to offline issuance.
Before the launch of the callback mechanism, the initial number of offline shares issued this time was 351645 million, accounting for 70.00% of the number issued after deducting the initial strategic placement; The initial number of shares issued online was 150705 million, accounting for 30.00% of the number issued after deducting the initial strategic placement. The total quantity of final offline and online issuance is the total quantity of this issuance minus the final strategic placement quantity. The final offline and online issuance quantity will be determined according to the call back situation. The final offline and online issuance quantity and strategic placement will be specified in the announcement of initial public offering and initial placement results of offline issuance of Guangdong taienkang Pharmaceutical Co., Ltd. listed on the gem published on March 22, 2022 (T + 2).
In order to facilitate public investors to understand the issuer’s basic situation, development prospects and relevant arrangements for subscription of this issuance, the issuer and the sponsor (lead underwriter) will hold an online roadshow on this issuance.
1. Online roadshow time: 14:00-17:00 on March 17, 2022 (t-1);
2. Online roadshow website: panorama (website: http://rs.p5w.net. ）；
3. Participants: key members of the issuer’s management and relevant personnel of the sponsor (lead underwriter).
Investors who intend to participate in this subscription should read the website designated by the CSRC on March 10, 2022 (T-6) (http://www.cn.info.com.cn; www.cs.com.cn; www.cn.stock.com; www.stcn.com; www.zqrb.cn) The full text of the prospectus and relevant information on.
Please pay attention to it.
Issuer: sponsor (lead underwriter) of Guangdong taienkang Pharmaceutical Co., Ltd.: Guotai Junan Securities Co.Ltd(601211) March 16, 2022
(there is no text on this page, which is the seal page of the online roadshow announcement of Guangdong taienkang Pharmaceutical Co., Ltd. on initial public offering and listing on the GEM)
Guangdong taienkang Pharmaceutical Co., Ltd
(there is no text on this page, which is the seal page of the online roadshow announcement of Guangdong taienkang Pharmaceutical Co., Ltd. on initial public offering and listing on the GEM)
Guotai Junan Securities Co.Ltd(601211) mm / DD / yyyy
